CCC
VKTX icon

Crescent Capital Consulting’s Viking Therapeutics VKTX Stock Holding History

Crescent Capital Consulting’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed – – 538
2021
Q1 		$0 Buy
+1
New +$7 ﹤0.01% 553

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Crescent Capital Consulting's VKTX Position: Q2 2021 in Review

Crescent Capital Consulting sold out of Viking Therapeutics (VKTX) in Q2 2021, closing a stake of 1 share.

Crescent Capital Consulting first reported a position in VKTX in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2021.

  • Crescent Capital Consulting reported no remaining Viking Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Crescent Capital Consulting sold 1 Viking Therapeutics share in Q2 2021.
  • Crescent Capital Consulting first reported a position in Viking Therapeutics in Q1 2021 and held it in 1 quarter.
  • Crescent Capital Consulting's Viking Therapeutics position peaked at $0 in Q1 2021.
  • 138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2021.

Based on Crescent Capital Consulting's 13F filing for Q2 2021, filed 15 Jul 2021.